Exploring α7-nicotinic receptor ligand diversity by scaffold enumeration from the chemical universe database GDB

ACS Medicinal Chemistry Letters

Volumn 1, Issue 8, 2010, Pages 422-426

  Garcia Delgado, Noemi ^a   Bertrand, Sonia ^b   Nguyen, Kong T ^a   Van Deursen, Ruud ^a   Bertrand, Daniel ^b   Reymond, Jean Louis ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Medical Faculty   (Switzerland)

Author keywords

docking; electrophysiology; nicotinic receptor; Virtual libraries; virtual screening

Indexed keywords

ACETYLCHOLINE; BUNGAROTOXIN RECEPTOR; QUINUCLIDINE; SCAFFOLD PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; DATA BASE; IC 50; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; XENOPUS;

EID: 77957931840     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100125f     Document Type: Article

References (31)

1. Billingsley, M. L. Druggable targets and targeted drugs: enhancing the development of new therapeutics Pharmacology 2008, 82, 239-244
2. Schneider, G.; Hartenfeller, M.; Reutlinger, M.; Tanrikulu, Y.; Proschak, E.; Schneider, P. Voyages to the (un)known: Adaptive design of bioactive compounds Trends Biotechnol. 2009, 27, 18-26
3. Reymond, J. L.; Van Deursen, R.; Blum, L. C.; Ruddigkeit, L. Chemical space as a source for new drugs Med. Chem. Commun. 2010, 1, 30-38
4. Fink, T.; Bruggesser, H.; Reymond, J. L. Virtual exploration of the small-molecule chemical universe below 160 Da Angew. Chem., Int. Ed. 2005, 44, 1504-1508
5. Fink, T.; Reymond, J. L. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: Assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery J. Chem. Inf. Model. 2007, 47, 342-353
6. Blum, L. C.; Reymond, J. L. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13 J. Am. Chem. Soc. 2009, 131, 8732-8733
7. Nguyen, K. T.; Syed, S.; Urwyler, S.; Bertrand, S.; Bertrand, D.; Reymond, J. L. Discovery of NMDA glycine site inhibitors from the chemical universe database GDB ChemMedChem 2008, 3, 1520-1524
8. Nguyen, K. T.; Luethi, E.; Syed, S.; Urwyler, S.; Bertrand, S.; Bertrand, D.; Reymond, J. L. 3-(Aminomethyl)piperazine-2,5-dione as a novel NMDA glycine site inhibitor from the chemical universe database GDB Bioorg. Med. Chem. Lett. 2009, 19, 3832-3835
9. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680
10. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
11. Wermuth, C. G. Similarity in drugs: reflections on analogue design Drug Discovery Today 2006, 11, 348-354
12. Bodnar, A. L.; Cortes-Burgos, L. A.; Cook, K. K.; Dinh, D. M.; Groppi, V. E.; Hajos, M.; Higdon, N. R.; Hoffmann, W. E.; Hurst, R. S.; Myers, J. K.; Rogers, B. N.; Wall, T. M.; Wolfe, M. L.; Wong, E. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors J. Med. Chem. 2005, 48, 905-908
13. Biton, B.; Bergis, O. E.; Galli, F.; Nedelec, A.; Lochead, A. W.; Jegham, S.; Godet, D.; Lanneau, C.; Santamaria, R.; Chesney, F.; Leonardon, J.; Granger, P.; Debono, M. W.; Bohme, G. A.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Vige, X.; Voltz, C.; Rouquier, L.; Souilhac, J.; Santucci, V.; Gueudet, C.; Francon, D.; Steinberg, R.; Griebel, G.; Oury-Donat, F.; George, P.; Avenet, P.; Scatton, B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile Neuropsychopharmacology 2007, 32, 1-16
14. Taly, A.; Corringer, P. J.; Guedin, D.; Lestage, P.; Changeux, J. P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discovery 2009, 8, 733-750
15. Paleari, L.; Cesario, A.; Fini, M.; Russo, P. alpha7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma? Drug Discovery Today 2009, 14, 822-836
16. Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential ChemMedChem 2007, 2, 746-767
17. Celie, P. H.; van Rossum-Fikkert, S. E.; van Dijk, W. J.; Brejc, K.; Smit, A. B.; Sixma, T. K. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures Neuron 2004, 41, 907-914
18. Ulens, C.; Akdemir, A.; Jongejan, A.; van Elk, R.; Bertrand, S.; Perrakis, A.; Leurs, R.; Smit, A. B.; Sixma, T. K.; Bertrand, D.; de Esch, I. J. Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis J. Med. Chem. 2009, 52, 2372-2383
19. Feuerbach, D.; Lingenhoehl, K.; Olpe, H. R.; Vassout, A.; Gentsch, C.; Chaperon, F.; Nozulak, J.; Enz, A.; Bilbe, G.; McAllister, K.; Hoyer, D. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain Neuropharmacology 2009, 56, 254-263
20. Walker, D. P.; Wishka, D. G.; Piotrowski, D. W.; Jia, S.; Reitz, S. C.; Yates, K. M.; Myers, J. K.; Vetman, T. N.; Margolis, B. J.; Jacobsen, E. J.; Acker, B. A.; Groppi, V. E.; Wolfe, M. L.; Thornburgh, B. A.; Tinholt, P. M.; Cortes-Burgos, L. A.; Walters, R. R.; Hester, M. R.; Seest, E. P.; Dolak, L. A.; Han, F.; Olson, B. A.; Fitzgerald, L.; Staton, B. A.; Raub, T. J.; Hajos, M.; Hoffmann, W. E.; Li, K. S.; Higdon, N. R.; Wall, T. M.; Hurst, R. S.; Wong, E. H.; Rogers, B. N. Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists Bioorg. Med. Chem. 2006, 14, 8219-8248
21. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662
22. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
23. Sadowski, J.; Gasteiger, J. From Atoms and Bonds to 3-Dimensional Atomic Coordinates-Automatic Model Builders Chem. Rev. 1993, 93, 2567-2581
24. Rush, T. S., 3rd; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction J. Med. Chem. 2005, 48, 1489-1495
25. Hogg, R. C.; Bandelier, F.; Benoit, A.; Dosch, R.; Bertrand, D. An automated system for intracellular and intranuclear injection J. Neurosci. Methods 2008, 169, 65-75
26. Guryn, R. Synthesis of 1,5-Diazabicyclo[5.3.0]Decane and 1,5-Diazabicyclo[5.4.0]Undecane Pol. J. Chem. 1985, 59, 1243-1246
27. Reyniers, F. S.; Borremans, F. A. M.; Anteunis, M. J. O. Solution Conformation of Cyclic Dipeptides of Pipecolic and Thiapipecolic Acid Combined with Glycine and Sarcosine Bull. Soc. Chim. Belges 1985, 94, 413-419
28. Bradsher, C. K.; Telang, S. A. 2-Azaquinolizinium Oxides J. Org. Chem. 1966, 31, 941-943
29. Majchrzak, M.; Kotelko, A.; Guryn, R. Derivatives of Octahydrodiazocine- 1,5 and Octahydrodiazocine-1,4 with Potential Pharmacological Action.1. Synthesis of N-Alkyl Derivatives of Octahydrodiazocine-1,5 and Octahydrodiazocine-1,4 Acta Pol. Pharm. 1975, 32, 145-148
30. Oka, M.; Matsumoto, Y.; Hirooka, K.; Suzuki, T. Synthesis of 1-azabicyclo[3.3.0]octane derivatives and their effects as piracetam-like nootropics Chem. Pharm. Bull. 2000, 48, 1121-1124
31. Suzuki, T.; Oka, M.; Maeda, K.; Furusawa, K.; Mitani, T.; Kataoka, T. N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-2-nitroaniline, a potent muscarinic agonist Chem. Pharm. Bull. (Tokyo) 1997, 45, 1218-1220